SynChem, Inc. wins Lilly’s 2002 Supplier AwardAugust 9, 2002
SynChem, Inc. was selected as one of Eli Lilly and Company's 2002 Supplier Award winners! There are 18 award winners for this year's suppliers throughout Lilly, including four in its research division. SynChem's representatives attended the awards presentation on August 8, 2002.
|
|
|
SynChem, Inc. and Neurocrine Biosciences, Inc. signed a collaboration agreement for combinatorial chemistryJuly 22, 2002 (see story from biospace)
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and SynChem, Inc. today announced that they have signed an agreement for the design and synthesis of a combinatorial chemistry template around small molecules targeted at the super-family of receptors called G protein coupled receptors (GPCRs). Under the terms of the agreement, SynChem will combine its expertise in the synthesis of new combinatorial chemistry templates with Neurocrine’s computational methodology and high throughput synthesis to design and synthesize a library targeted at GPCRs. Both companies will contribute unique, proprietary chemical templates to the Collaboration. Neurocrine has several research programs based on GPCRs, which serve as targets for the identification of novel therapeutics. "We are delighted to initiate this combinatorial chemistry collaboration with Neurocrine. We look forward to achieving success on behalf of Neurocrine and expanding our list of partners for whom we can provide this very valuable service” said Dr. W. Paul Mar, President and CEO of SynChem, Inc. “This is an excellent way for us acquire the complex intermediates that we need to develop our GPCR screening library which has been designed specifically for GPCR’s activated by peptide ligands” said John Saunders, Ph.D. Vice President of Research Chemistry for Neurocrine Biosciences. Neurocrine Biosciences is a leading neuroscience company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The Company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, Alzheimer's disease, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes. SynChem, Inc. is a privately held contract research organization providing research services in all aspects of organic chemistry. SynChem complements the experience of its researchers with proprietary tools in organic chemistry and combinatorial chemistry building blocks.
|
|
|
SynChem International Corporation, Inc., an affiliate of SynChem, Inc. setupJune 15, 2002
SynChem International Corporation, Inc. is setup on June 15, 2002 as a management body for SynChem (China), Ltd. SynChem, Inc. will integrate its custom chemical synthesis and contract research service through SynChem International Corporation with SynChem (China), Ltd. SynChem, Inc. at Chicago offers the time-sensitive service for its customers while SynChem (China), Ltd. offers the cost-sensitive FTE (Full Time Employee) contract research service through SynChem International Corporation.
|
|
|
SynChem (China), Ltd. setupApril 10, 2002
SynChem (China), Ltd., a Chinese affiliate of SynChem, Inc. was setup in Shanghai, China. Dr. W. Paul Mar is appointed as Chairman of Board, and Dr. Daniel Fang is appointed as Chief Executive Officer and President, Dr. Larry Huang as Chief Scientific Officer. SynChem (China), Ltd. will be expanded from current 5 employees to 32 employees by this September and will focus on the FTE contract research projects for its customers. Its customers list included Eli Lilly and Company and other biotech and drug discover companies.
|
|
|
|
by Jeff Bergau i-street magzine/March 2002/ www.i-street.com
|